Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Coeptis Therapeutics Hldgs Inc (COEP)

$12.11 +0.29 (2.45%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	64.67M
Revenue (ttm)	0.00
Net Income (ttm)	-10.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	35,200
Avg Vol	78,684
Day's Range	N/A - N/A
Shares Out	5.34M
Stochastic %K	41%
Beta	-0.50
Analysts	Strong Buy
Price Target	$3.00

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology

Sector: Healthcare

Phone: 724 934 6467

Website: coeptistx.com

Address:

105 Bradford Road, Suite 420, Wexford, United States

Bulllllllllllllllllllll Feb. 16 at 2:06 AM

$COEP

0 · Reply

KongMode Feb. 16 at 12:20 AM

$VTGN $OCGN $COEP $CADL #{}{

0 · Reply

candlestickmaster Feb. 15 at 6:03 AM

$COEP been waiting... Soon

0 · Reply

newdmontheblock Feb. 15 at 5:58 AM

$COEP DOGE pumping just in time. Gonna make a lot of money this week.

0 · Reply

Bulllllllllllllllllllll Feb. 15 at 5:21 AM

$COEP

0 · Reply

ARizzo28 Feb. 15 at 4:03 AM

$COEP hopefully a big week with merger and $DOGE.X

0 · Reply

kobramaximus Feb. 14 at 11:56 PM

$COEP ⏰️💣

0 · Reply

Bulllllllllllllllllllll Feb. 14 at 11:25 PM

$COEP Dogecoin's Crazy COEP Super Strong

0 · Reply

Bulllllllllllllllllllll Feb. 14 at 11:17 PM

$COEP Dogecoin merger, 9000 miners, merger fair price $50+, Tuesday $100, it's going to be crazy!

0 · Reply

Bulllllllllllllllllllll Feb. 14 at 11:14 PM

$COEP Trending #1 COEP Tuesday $100+ Dogecoin Super Strong, Banga 13G Stake

0 · Reply

Coeptis Receives Shareholder Approval Towards Z Squared Merger

Jan 6, 2026, 8:19 AM EST - 5 weeks ago

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

Sep 23, 2025, 8:00 AM EDT - 5 months ago

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Jul 22, 2025, 8:36 AM EDT - 7 months ago

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Jun 26, 2025, 8:34 AM EDT - 8 months ago

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

May 28, 2025, 8:28 AM EDT - 9 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Apr 25, 2025, 8:33 AM EDT - 10 months ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 17, 2025, 8:38 AM EDT - 10 months ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Mar 11, 2025, 8:34 AM EDT - 1 year ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 7, 2025, 8:37 AM EST - 1 year ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 1 year ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

Feb 20, 2025, 9:00 AM EST - 1 year ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 7:27 AM EST - 1 year ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 13, 2025, 8:39 AM EST - 1 year ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 6, 2025, 8:08 AM EST - 1 year ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 30, 2025, 8:27 AM EST - 1 year ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 3, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Nov 7, 2024, 8:07 AM EST - 1 year ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Oct 24, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 15, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Sep 19, 2024, 7:07 AM EDT - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 5, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

Jun 20, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Apr 2, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Feb 26, 2024, 9:00 AM EST - 2 years ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 7, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Jan 4, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Dec 4, 2023, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 24, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

$Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection$